Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...

Mia Cassella told Newsweek: "Cancer might take away things like my hair or my energy, but it couldn't take away my passion for lifting and working out." ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental ...

Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...

New York–based hematologist-oncologist and clinical researcher works to lower the barriers to enrolling in clinical trials.

Lymphoma cancer is also among the top 10 types of cancer detected among Malaysians. The PAL Scheme provides free second-line ...

Pfizer’s Takeda-partnered blood cancer drug Adcetris (brentuximab vedotin) has been approved by the US Food and Drug ...

the researchers showed the benefit of combining chemotherapy with immunotherapy for DLBCL. The results, published in the journal Blood, offer new hope for patients whose lymphoma has returned or ...

Among older adults with classical Hodgkin lymphoma, frontline N-AVD has been found to be highly effective and well-tolerated.

Fraser Wood, 7, was diagnosed with a type of blood cancer known as lymphoblastic lymphoma after becoming ill over the summer ...

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application ...